ABL is a contract research and manufacturing service provider, specializing in the development of vaccines and biotherapeutics for preclinical and clinical studies. For more than 50 years, the discoveries made in ABL’s laboratories have offered insights into the workings of the immune system and the pathogenesis of some of the most complex and daunting diseases.
In collaboration with Dr. Robert Gallo in the 1970s, scientists at ABL (then called Litton Bionetics) isolated and characterized interleukin 2 (IL-2 ). In the 1980s, the first known human retroviruses (HTLV-I and HTLV-II) and the human B cell leukemia virus (HHV-6) were isolated and characterized at ABL. ABL scientists were also part of the team that co-discovered HIV-1 and developed the first HIV-1 ELISA-based diagnostic blood test.
Over the last 30 years, ABL scientists have developed assays and in vivo models to evaluate immune responses in clinical and preclinical settings. To evaluate human and animal samples, ABL has developed humoral and cellular assays to measure immunogenicity, molecular assays aimed at measuring drug and vaccine efficacy, and assays to quantify biomarkers of diseases such as dengue, cancer, and HIV.
Over the last 15 years, ABL has enhanced capabilities in cGMP biopharmaceutical production for the development and production of vaccines, such as DNA prime/boost vaccines, and therapeutics aimed at the prevention and treatment of a wide variety of diseases including cardiovascular disease, cancer, filovirus infection, plague, and other infectious diseases. Today, ABL draws from its decades of experience with diverse product types applying proven scientific techniques and protocols to drive innovative development and discovery.